Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 5/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103384 | 0.82 | ALDH1A1 (0.57) | ADORA2BADORA2AMAPK14KDM4EALDH1A1 | |
| SCHEMBL5205345 | 0.72 | TGFBR1 (0.53) | ADORA2BADORA2AMAPK14KDM4EALDH1A1 | |
| SCHEMBL13740640 | 0.72 | MAPK14 (0.53) | ADORA2AMAPK14ALDH1A1MAPT | |
| SCHEMBL11753803 | 0.72 | LMNA (0.50) | ADORA2BADORA2AMAPK14KDM4EALDH1A1 | |
| SCHEMBL4096817 | 0.72 | KCNH2 (0.46) | ADORA2BADORA2AMAPK14MAP4K4MINK1 | |
| SCHEMBL11753828 | 0.71 | PTGS2 (0.50) | PTGS2 | |
| SCHEMBL11751421 | 0.70 | LMNA (0.57) | ADORA2BADORA2AKDM4EALDH1A1MAPT | |
| SCHEMBL2798070 | 0.70 | MAPK14 (0.72) | MAPK14PTGS2 | |
| SCHEMBL5813696 | 0.69 | MAPK14 (0.60) | ADORA2BADORA2AMAPK14MAP4K4MINK1 | |
| SCHEMBL5816366 | 0.69 | MAPK14 (0.48) | ADORA2BADORA2AMAPK14KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513827-A1 | 1,3,5-TRIAZINE DERIVATIVES AS LIGANDS FOR HUMAN ADENOSINE-A3 RECEPTORS | Solvay Pharmaceuticals B.V. (NL) | 2005-03-16 | — | — | EP | claimed |
| WO-2003101980-A1 | 1,3,5-TRIAZINE DERIVATIVES AS LIGANDS FOR HUMAN ADENOSINE-A3 RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-12-11 | — | — | WO | claimed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2005105814-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1513827-A1 | 1,3,5-TRIAZINE DERIVATIVES AS LIGANDS FOR HUMAN ADENOSINE-A3 RECEPTORS | Solvay Pharmaceuticals B.V. (NL) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101980-A1 | 1,3,5-TRIAZINE DERIVATIVES AS LIGANDS FOR HUMAN ADENOSINE-A3 RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | ADORA2B 4778/4885ADORA2A 4577/4885MAPK14 136/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | ADORA2B 4778/4885ADORA2A 4577/4885MAPK14 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.